Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the digestive tract. The clinical
behavior of GISTs varies greatly, has extended follow-up, and almost all of the tumors have …

Imatinib mesylate is used for the treatment of patients with Philadelphia chromosome–
positive chronic myeloid leukemia and gastrointestinal stromal tumors (GISTs). It has been …

Background The use of imatinib mesylate is associated with a progression free survival of 41
months in first line treatment of metastatic or locally advanced gastrointestinal stromal …

We report the first case of hepatocellular injury occurring in a patient treated for metastatic
gastrointestinal stromal tumour (GIST) with imatinib mesylate, with two positive rechallenges …

Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal
stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its …

Background Imatinib mesylate has been used for the treatment of unresectable or metastatic
gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 …

The rupture or bleeding of a gastrointestinal stromal tumor (GIST) is a life-threatening
adverse event that can happen during imatinib therapy, but few such cases have been …

Background: Molecularly targeted therapy has revolutionized the treatment of advanced
gastrointestinal stromal tumors (GISTs). Specifically, the consistent dependence of GISTs on …

Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid
leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced …

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms that may affect
any portion of the gastrointestinal tract. Surgical resection was previously considered the …